Control of cardiovascular risk factors in type 2 diabetes in a specialized diabetic clinic
DOI:
https://doi.org/10.23938/ASSN.0089Keywords:
Type 2 diabetes mellitus. Cardiovascular risk factors. HbA1c. LDL-cholesterol. Blood pressure.Abstract
Background. Achieving an adequate control of glycaemic and cardiovascular risk factors (CVRFs) is essential in patients with type 2 diabetes mellitus (T2DM). However, several studies have shown that the percentage of patients achieving these goals is scarce. We evaluated the degree of control of CVRFs target goals in T2DM patients who regularly attend a specialized diabetic clinic.
Methods. We studied T2DM patients who came to a review at the Department of Endocrinology with a minimum follow-up of 1 year. Clinical characteristics, chronic complications and treatments were collected and patients were classified into groups according to the fulfilment of target glycated haemoglobin (HbA1c), LDL cholesterol and blood pressure (BP) levels, predefined according to the presence of different comorbidities and the duration of T2DM.
Results. We analysed 137 patients (75% men) with T2DM, with an average age of 67 years and a 12.7 year duration of diabetes. During follow-up, 83.9% of the patients were within the individualized HbA1c target, 76.6% considering BP and 67.2% in terms of LDL-cholesterol. In addition, 68% had concomitantly the three main variables within the target.
Conclusions. In our population of T2DM, HbA1c, LDL cholesterol and BP targets were achieved in a substantial proportion of patients (67-91%). Perhaps the intense and individualized care offered through a specialized diabetes unit may explain these results.
Downloads
References
ORTEGA E, AMOR AJ, ROJO-MARTINEZ G, CASTELL C, GIMENEZ M, CONGET I. Cardiovascular disease in patients with type 1 and type 2 diabetes in Spain. Med Clin (Barc) 2015; 145: 233-238.
FRANCH-NADAL J, MATA-CASES M, VINAGRE I, PATITUCCI F, HERMOSILLA E, CASELLAS A et al. Differences in the cardiometabolic control in type 2 diabetes according to gender and the presence of cardiovascular disease: results from the eControl study. Int J Endocrinol 2014; 2014: 131709.
SAYDAH SH, EBERHARDT MS, LORIA CM, BRANCATI FL. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002; 156: 714-719.
STAMLER J, VACCARO O, NEATON JD, WENTWORTH D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
INZUCCHI SE, BERGENSTAL RM, BUSE JB, DIAMANT M, FERRANNINI E, NAUCK M et al. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
GAEDE P, VEDEL P, LARSEN N, JENSEN GV, PARVING HH, PEDERSEN O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
GAEDE P, VEDEL P, PARVING HH, PEDERSEN O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617-622.
TITCHENER J. A patient-centred clinical approach to diabetes care assists long-term reduction in HbA1c. J Prim Health Care 2014; 6: 195-202.
SMITH RJ, NATHAN DM, ARSLANIAN SA, GROOP L, RIZZA RA, ROTTER JI. Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 2010; 95: 1566-1574.
ADVANCE COLLABORATIVE GROUP, PATEL A, MACMAHON S, CHALMERS J, NEAL B, BILLOT L et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572.
BOUSSAGEON R, BEJAN-ANGOULVANT T, SAADATIAN-ELAHI M, LAFONT S, BERGEONNEAU C, KASSAI B et al. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d4169.
HAYWARD RA, REAVEN PD, WIITALA WL, BAHN GD, REDA DJ, GE L et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015; 372: 2197-2206.
KIRKMAN MS, MCCARREN M, SHAH J, DUCKWORTH W, ABRAIRA C; VADT STUDY GROUP. The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes. J Diabetes Complications 2006; 20: 75-80.
VINAGRE I, MATA-CASES M, HERMOSILLA E, MORROS R, FINA F, ROSELL M et al. Control of glycemia and cardiovascular risk factors in patients with type 2 diabetes in primary care in Catalonia (Spain). Diabetes Care 2012; 35: 774-779.
JURADO J, YBARRA J, SOLANAS P, CAULA J, GICH I, POU JM et al. Prevalence of cardiovascular disease and risk factors in a type 2 diabetic population of the North Catalonia diabetes study. J Am Acad Nurse Pract 2009; 21: 140-148.
ROCA-RODRIGUEZ MM, CARRAL-SAN LAUREANO F, BAENA-NIETO G, AGUILAR-DIOSDADO M. Evaluation of metabolic control targets in patients with type 2 diabetes mellitus. Endocrinol Nutr 2010; 57: 434-439.
ALI MK, BULLARD KM, SAADDINE JB, COWIE CC, IMPERATORE G, GREGG EW. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med 2013; 368: 1613-1624.
HANDELSMAN Y, BLOOMGARDEN ZT, GRUNBERGER G, UMPIERREZ G, ZIMMERMAN RS, BAILEY TS et al. American association of clinical endocrinologists and american college of endocrinology - clinical practice guidelines for developing a diabetes mellitus comprehensive care plan - 2015. Endocr Pract 2015; 21 (Suppl 1): 1-87.
AMERICAN DIABETES ASSOCIATION. Standards of Medical Care in Diabetes. Diabetes Care 2016; 39 (Suppl. 1): S13-S22.
OSTERBERG L, BLASCHKE T. Adherence to medication. N Engl J Med 2005; 353: 487-497.
HERMIDA RC, MOYA A, AYALA DE. Ambulatory blood pressure monitoring in diabetes for the assessment and control of vascular risk. Endocrinol Nutr 2015; 62 (Suppl. 8): 400-410.
HERMIDA RC, AYALA DE, MOJON A, FERNANDEZ JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. Chronobiol Int 2010; 27: 1629-1651.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
